Metastatic Oncogen-driven Cancer Clinical Trial
— MATCH-ROfficial title:
A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents
| Verified date | August 2023 |
| Source | Gustave Roussy, Cancer Campus, Grand Paris |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a prospective study to identify molecular mechanisms of acquired resistance to targeted therapies in patients with unresectable or metastatic cancer. This is a protocol to study clinical characteristics and biopsy tissue of patients with oncogene-driven cancer who have had previous clinical response to targeted therapy and subsequently experience progression of disease. The tissues and other specimens will be used to carry out laboratory studies to explore the molecular basis of acquired resistance to targeted therapies.
| Status | Active, not recruiting |
| Enrollment | 1500 |
| Est. completion date | March 2025 |
| Est. primary completion date | November 18, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: Patients diagnosed with confirmed cancer and who fulfill the following eligibility criteria will be considered eligible for this study: 1. Patient affiliated to a social security regimen 2. Patients scheduled to receive anticancer agents or currently receiving anticancer agents 3. Tumor lesion accessible to core biopsies (malignant effusions can represent an alternative) 4. Patient who is fully informed, able to comply with the protocol and who signed the informed consent. 5. Availability of initial tumor material (ideally frozen, or non-Bouin fixed paraffin embedded material) acquired before exposure to the targeted therapy Note: Patients may have received other treatments since treatment with targeted therapies including radiation or chemotherapy, before undergoing the study biopsy. Exclusion Criteria: 1. Coagulation abnormality prohibiting a biopsy |
| Country | Name | City | State |
|---|---|---|---|
| France | Gustave Roussy Cancer Campus Grand Paris | Villejuif | Val De Marne |
| Lead Sponsor | Collaborator |
|---|---|
| Gustave Roussy, Cancer Campus, Grand Paris |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Type and frequency of molecular alterations in resistant tumors using whole exome sequencing | 30 days after inclusion |